Last Updated: October 2, 2026

Claims for Patent: 12,569,474

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,569,474

Title:	Compositions and methods for treating anemia
Abstract:	Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Inventor(s):	Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
Assignee:	Akebia Therapeutics Inc
Application Number:	US18/511,042
Patent Claims:	1. A method for treating anemia secondary to or associated with chronic kidney disease, comprising orally administering to a patient having said anemia a once daily dose of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, or a pharmaceutically acceptable salt thereof, wherein said once daily dose is 150 mg, 300 mg, 450 mg, or 600 mg of Compound 1. 2. The method of claim 1, wherein the patient has pre-dialysis chronic kidney disease. 3. The method of claim 2, wherein the once daily dose is 150 mg of Compound 1. 4. The method of claim 2, wherein the once daily dose is 300 mg of Compound 1. 5. The method of claim 2, wherein the once daily dose is 450 mg of Compound 1. 6. The method of claim 2, wherein the once daily dose is 600 mg of Compound 1. 7. The method of claim 1, wherein the patient is a dialysis patient. 8. The method of claim 7, wherein the once daily dose is 150 mg of Compound 1. 9. The method of claim 7, wherein the once daily dose is 300 mg of Compound 1. 10. The method of claim 7, wherein the once daily dose is 450 mg of Compound 1. 11. The method of claim 7, wherein the once daily dose is 600 mg of Compound 1. 12. The method of claim 1, wherein the patient has stage 3, 4, or 5 chronic kidney disease. 13. The method of claim 12, wherein the once daily dose is 150 mg of Compound 1. 14. The method of claim 12, wherein the once daily dose is 300 mg of Compound 1. 15. The method of claim 12, wherein the once daily dose is 450 mg of Compound 1. 16. The method of claim 12, wherein the once daily dose is 600 mg of Compound 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.